Κατάλογος ενδεικτικών δημοσιεύσεων του τμήματος Ιατρικής ΑΠΘ σε διεθνή επιστημονικά περιοδικά κατά τα τελευταία 5 έτη.
Export 369 results:
Συντάκτης Τίτλος Τύπος [ Έτος] Φίλτρα: Συντάκτης is Polyzos, Stergios A [Clear All Filters]
Hypophosphatasia..
J Clin Med. 10(23),
(2021). Impact of Helicobacter pylori-related Metabolic Syndrome and Gastroesophageal Reflux Disease on the Risk of Acute Myocardial Infarction..
J Neurogastroenterol Motil. 27(1), 147-148.
(2021). Impact of -Related Metabolic Syndrome Parameters on Arterial Hypertension..
Microorganisms. 9(11),
(2021). Impact of -related Microbial Dysbiosis in the Pathogenesis of Metabolic Syndrome and Gastrointestinal Dysmotility Disorders..
J Neurogastroenterol Motil. 27(4), 653-654.
(2021). Inflammatory Bowel Disease-associated Fatty Liver Disease: the Potential Effect of Biologic Agents..
J Crohns Colitis.
(2021). Irisin in nonalcoholic fatty liver disease: Need for an updated meta-analysis..
Metabolism. 121, 154818.
(2021). Long-term statin treatment for hepatic fibrosis in patients with nonalcoholic fatty liver disease: Is it time to give the emperor a statin robe?.
Metabolism. 121, 154796.
(2021). Micro-Ultrasound-guided Versus Multiparametric Magnetic Resonance Imaging-Targeted Biopsy in the Detection of Prostate Cancer: A Systematic Review and Meta-Analysis..
J Urol. 101097JU0000000000001639.
(2021). Nonalcoholic fatty liver disease: lifestyle and quality of life..
Hormones (Athens).
(2021). Postmenopausal osteoporosis coexisting with other metabolic diseases: Treatment considerations..
Maturitas. 147, 19-25.
(2021). Potential impact of Helicobacter pylori-related metabolic syndrome and Galectin-3 on liver, chronic kidney and brain disorders..
Metabolism. 154736.
(2021). A potential impact of Helicobacter pylori-related sarcopenia on severity of portal hypertension..
Liver Int.
(2021). Review article: non-alcoholic fatty liver disease and cardiovascular diseases: associations and treatment considerations..
Aliment Pharmacol Ther.
(2021). Role of autophagy in gastric carcinogenesis..
World J Gastrointest Oncol. 13(10), 1244-1262.
(2021). Sodium-glucose co-transporter 2 inhibitors in nonalcoholic fatty liver disease..
Eur J Pharmacol. 907, 174272.
(2021). The trimebutine effect on Helicobacter pylori-related gastrointestinal tract and brain disorders: A hypothesis..
Neurochem Int. 144, 104938.
(2021). Ιrisin levels in postmenopausal women with an incident hip fracture..
Endocrine. 73(3), 719-722.
(2021). Active Infection is Independently Associated with Nonalcoholic Steatohepatitis in Morbidly Obese Patients..
J Clin Med. 9(4),
(2020). Alzheimer's disease and gastrointestinal microbiota; impact of infection involvement..
Int J Neurosci. 1-13.
(2020). Association between Active Infection and Glaucoma: A Systematic Review and Meta-Analysis..
Microorganisms. 8(6),
(2020). Combination and sequential treatment in women with postmenopausal osteoporosis..
Expert Opin Pharmacother. 21(4), 477-490.
(2020). Commentary: Nonalcoholic or metabolic dysfunction-associated fatty liver disease? The epidemic of the 21st century in search of the most appropriate name..
Metabolism. 113, 154413.
(2020). Comparative effectiveness of glucagon-like peptide-1 receptor agonists versus dipeptidyl peptidase-4 inhibitors on noninvasive indices of hepatic steatosis and fibrosis in patients with type 2 diabetes mellitus..
Diabetes Metab Syndr. 14(6), 1913-1919.
(2020). Current and emerging pharmacological options for the treatment of nonalcoholic steatohepatitis..
Metabolism. 154203.
(2020). Dissociating nonalcoholic steatohepatitis from hepatocellular carcinoma in obesity..
Hepatobiliary Surg Nutr. 9(1), 73-76.
(2020).